You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
McKinsey
Express Scripts
Mallinckrodt
Colorcon

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,765,150

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,765,150
Title:Riluzole aqueous suspensions
Abstract: Physically and chemically stable aqueous oral suspensions of riluzole and manufacturing methods thereof. The suspensions contain riluzole in particle form and at least a wetting agent, preferably a surfactant. Riluzole is present in amounts from about 0.1% to about 20% w/v and has an average particle size lower than 200 .mu.m. The suspensions are devoid of the known local (mouth) anaesthetic effects of riluzole.
Inventor(s): Artico; Roberta (Milan, IT), Adami; Marco (Milan, IT), Barbareschi; Daniele (Milan, IT), Moscoso; Jaime (Alcoendas, ES), Oldoni; Tiziano (Milan, IT), Mascagni; Paolo (Milan, IT)
Assignee: Italfarmaco SpA (Milan, IT)
Application Number:13/138,047
Patent Claim Types:
see list of patent claims
Use; Compound;

Drugs Protected by US Patent 8,765,150

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Italfarmaco Spa TIGLUTIK KIT riluzole SUSPENSION;ORAL 209080-001 Sep 5, 2018 RX Yes Yes   Start Trial   Start Trial Y A METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS IN A PATIENT IN NEED OF SUCH TREATMENT, SAID METHOD COMPRISING ADMINISTERING TO SAID PATIENT AN EFFECTIVE AMOUNT OF A SUSPENSION ACCORDING TO CLAIM 1   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,765,150

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
09425101Mar 13, 2009
PCT Information
PCT FiledMarch 02, 2010PCT Application Number:PCT/EP2010/052598
PCT Publication Date:September 16, 2010PCT Publication Number: WO2010/102923

International Family Members for US Patent 8,765,150

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Brazil PI1006418   Start Trial
Canada 2748856   Start Trial
Chile 2011002217   Start Trial
China 102341091   Start Trial
Colombia 6410281   Start Trial
Cyprus 1113825   Start Trial
Denmark 2405890   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Colorcon
Moodys
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.